Poolbeg Pharma has been granted patents by the US Patent and Trademark Office for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections.
May 26, 2022
· 4 min read